Radiation treatment planning with FDG, PSMA and FAPI in different tumors
Recent advancements in imaging, particularly [18F]FDG PET/CT and [18F]PSMA-1007 have improved the detection of distant metastases including involved lymph nodes, thus influencing staging accuracy and potentially treatment outcomes. PET-CT is therefore implemented in radiation treatment planning to evaluate its impact versus computed tomography (CT) alone on radiation target volumes for involved-site radiotherapy (IS-RT) in different tumor entities.
Fig. 1 demonstrates multiple small lymph node metastases in [18F]PSMA-1007 in a patient with a primary high risk prostate cancer.
Cooperation with the CCU Clinical Cooperation Unit Radiation Therapy (Prof. Dr. Dr. Debus).
Fig.1. F-18-PSMA-1007 primary high risk prostate cacer